ERBB2 and non-small cell lung carcinoma: We reviewed the gene mutation prevalence in the patients with NSCLC, of the 93 cases, 26 were available of the data, which was 53.85% (14/26) for EGFR, 19.23% (5/26) for RAS, 11.54% (3/26) for ALK, 7.69% (2/26) for TP53, 3.85% (1/26) for Her‐2, and 3.85% (1/26) for RET.